Adjuvant Chemotherapy for Stage II Colon Cancer

Assessment of Duration and Effects of 3 vs 6 Months of Adjuvant Chemotherapy in High-Risk Stage II Colorectal Cancer

(2020) Fausto Petrelli et al.   JAMA Oncology

A new prognostic and predictive tool to enhance shared decision making in stage III colon cancer.

(2020) Alberto F. Sobrero et al.   JOURNAL OF CLINICAL ONCOLOGY

Localised Colon Cancer: ESMO Clinical Practice Guidelines for Diagnosis, Treatment and Follow-up

(2020) G. Argiles et al.   ANNALS OF ONCOLOGY

Lymphovascular Invasion and Perineural Invasion Negatively Impact Overall Survival for Stage II Adenocarcinoma of the Colon

(2019) Matthew Skancke et al.   DISEASES OF THE COLON & RECTUM

Prospective pooled analysis of four randomized trials investigating duration of adjuvant (adj) oxaliplatin-based therapy (3 vs 6 months {m}) for patients (pts) with high-risk stage II colorectal cancer (CC).

(2019) Timothy Iveson et al.   JOURNAL OF CLINICAL ONCOLOGY

Re-evaluating disease-free survival (DFS) as an endpoint versus overall survival (OS) in adjuvant colon cancer (CC) trials with chemotherapy +/- biologics: An updated surrogacy analysis based on 18,886 patients (pts) from the Accent database.

(2019) Qian Shi et al.   JOURNAL OF CLINICAL ONCOLOGY

Adjuvant therapy for stages II and III colon cancer: risk stratification, treatment duration, and future directions

(2019) U. Bender et al.   Current Oncology

Microsatellite instability and survival after adjuvant chemotherapy among stage II and III colon cancer patients: results from a population‐based study

(2019) Elizabeth Alwers et al.   Molecular Oncology

High-Risk Stage II Colon Cancer: Not All Risks Are Created Equal

(2018) Blake D. Babcock et al.   ANNALS OF SURGICAL ONCOLOGY

Emergent Colectomy Is Independently Associated with Decreased Long-Term Overall Survival in Colon Cancer Patients

(2017) Zhaomin Xu et al.   JOURNAL OF GASTROINTESTINAL SURGERY

Origins of lymphatic and distant metastases in human colorectal cancer

(2017) Kamila Naxerova et al.   SCIENCE

Adjuvant Fluorouracil, Leucovorin, and Oxaliplatin in Stage II to III Colon Cancer: Updated 10-Year Survival and Outcomes According toBRAFMutation and Mismatch Repair Status of the MOSAIC Study

(2015) Thierry André et al.   JOURNAL OF CLINICAL ONCOLOGY

Risk of recurrence in patients with colon cancer stage II and III: A systematic review and meta-analysis of recent literature

(2014) Camilla Böckelman et al.   ACTA ONCOLOGICA

Survival Paradox Between Stage IIB/C (T4N0) and Stage IIIA (T1-2N1) Colon Cancer

(2014) Min Jung Kim et al.   ANNALS OF SURGICAL ONCOLOGY

Comparison of Outcomes After Fluorouracil-Based Adjuvant Therapy for Stages II and III Colon Cancer Between 1978 to 1995 and 1996 to 2007: Evidence of Stage Migration From the ACCENT Database

(2013) Qian Shi et al.   JOURNAL OF CLINICAL ONCOLOGY

Evaluation of Relapse-Free Survival in T3N0 Colon Cancer: The Role of Chemotherapy, a Multicentric Retrospective Analysis

(2013) Roberta Grande et al.   PLoS One

A randomized phase III trial of adjuvant chemotherapy with irinotecan, leucovorin and fluorouracil versus leucovorin and fluorouracil for stage II and III colon cancer: A Hellenic Cooperative Oncology Group study

(2011) Christos A Papadimitriou et al.   BMC Medicine

Two or three year disease-free survival (DFS) as a primary end-point in stage III adjuvant colon cancer trials with fluoropyrimidines with or without oxaliplatin or irinotecan: Data from 12,676 patients from MOSAIC, X-ACT, PETACC-3, C-06, C-07 and C89803

(2011) D. Sargent et al.   EUROPEAN JOURNAL OF CANCER

Oxaliplatin As Adjuvant Therapy for Colon Cancer: Updated Results of NSABP C-07 Trial, Including Survival and Subset Analyses

(2011) Greg Yothers et al.   JOURNAL OF CLINICAL ONCOLOGY

Review: Combination therapy in high-risk stage II or stage III colon cancer: current practice and future prospects

(2010) Diogo Assed Bastos et al.   Therapeutic Advances in Medical Oncology

Randomized Phase III Trial Comparing Biweekly Infusional Fluorouracil/Leucovorin Alone or With Irinotecan in the Adjuvant Treatment of Stage III Colon Cancer: PETACC-3

(2009) Eric Van Cutsem et al.   JOURNAL OF CLINICAL ONCOLOGY

Perineural Invasion Is an Independent Predictor of Outcome in Colorectal Cancer

(2009) Catherine Liebig et al.   JOURNAL OF CLINICAL ONCOLOGY

Evidence for Cure by Adjuvant Therapy in Colon Cancer: Observations Based on Individual Patient Data From 20,898 Patients on 18 Randomized Trials

(2009) Daniel Sargent et al.   JOURNAL OF CLINICAL ONCOLOGY

Improved Overall Survival With Oxaliplatin, Fluorouracil, and Leucovorin As Adjuvant Treatment in Stage II or III Colon Cancer in the MOSAIC Trial

(2009) Thierry André et al.   JOURNAL OF CLINICAL ONCOLOGY

Revised TN Categorization for Colon Cancer Based on National Survival Outcomes Data

(2009) Leonard L. Gunderson et al.   JOURNAL OF CLINICAL ONCOLOGY

Identification of Patients with High-Risk Stage II Colon Cancer for Adjuvant Therapy

(2008) Hak-Mien Quah et al.   DISEASES OF THE COLON & RECTUM